Position in NSRX
as of Jun 30, 2026
· filed Sep 2, 2026
Position Value
$77,014
New position
Shares Held
22,004
first reported quarter
Ownership
0.188%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#6
of 10 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $3,979,998,649 across 21 Drug Manufacturers - General names. NSRX ranks #19 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
945,456 | $1,134,008,383 | |
| 2 | ABBV |
AbbVie Inc.
|
3,169,783 | $797,644,194 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
3,480,444 | $439,719,294 | |
| 4 | JNJ |
Johnson & Johnson
|
1,500,832 | $381,166,302 | |
| 5 | AMGN |
Amgen Inc
|
703,984 | $254,926,685 | |
| 6 | MRK |
Merck & Co., Inc.
|
1,933,667 | $248,476,209 | |
| 7 | AZN |
Astrazeneca PLC
|
970,043 | $183,939,553 | |
| 8 | PFE |
Pfizer Inc
|
6,191,186 | $149,083,758 |
All Filings in NSRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $77,014 | 22,004 | Shares | Defined | 2026-09-02 | |
| No filing history on record for this holder in this stock. | ||||||